Outi Kuittinen
Professor
Head of the Discipline
Institute of Clinical Medicine, School of Medicine, Faculty of Health Sciences
outi.kuittinen@uef.fi
Research groups
Publications
53/53 items-
Drug‐induced pneumonitis risk in diffuse large B‐cell/follicular lymphoma patients treated with R‐CHOP‐like regimen is associated with the use of granulocyte colony‐stimulating growth factors
Kaprio, Elina; Prusila, Roosa; Tokola, Susanna; Kuusisto, Milla E L; Jantunen, Esa; Kuitunen, Hanne; Turpeenniemi‐Hujanen, Taina; Kuittinen, Outi. 2024. Cancer medicine. 13: -
Elderly long-term survivors in the Nordic phase II study with first-line maintenance temozolomide for primary central nervous system lymphoma: a 10-year follow-up
Pulczynski, Elisa Jacobsen; Simonsen, Mikkel Runason; Kuittinen, Outi; Fagerli, Unn-Merete; Erlanson, Martin; Fluge, Øystein; Leppä, Sirpa; Østenstad, Bjørn; Fosså, Alexander; Eriksson, Mikael; El-Galaly, Tarec; Kuitunen, Hanne; Papworth, Karin; Ljungqvist, Maria; Pedersen, Martin B; Pollari, Marjukka. 2024. Haematologica: the hematology journal. [Epub ahead of print Mar 28, 2024 ]: 1-10 -
A practical prognostic peripheral blood-based risk model for the evaluation of the likelihood of a response and survival of metastatic cancer patients treated with immune checkpoint inhibitors
Tiainen, Satu; Nurmela, Veera; Selander, Tuomas; Turunen, Patrik; Pasonen-Seppänen, Sanna; Kettunen, Tiia; Kuittinen, Outi; Auvinen, Päivi; Rönkä, Aino. 2023. Bmc cancer. 23: . 1186 -
A retrospective study of treatment results of blood-brain barrier disruption (BBBD) based immunochemotherapy combined with autologous stem cell transplantation (ASCT) in patients with primary central nervous system lymphoma (PCNSL)
Kuitunen, H; Sonkajärvi, E; Oksman, M; Puhakka, I; Isokangas, M; Pyörälä, M; Jantunen, E; Marin, K; Aromaa-Häyhä, A; Rönkä, A; Auvinen, P; Kuittinen O. 2023. Annals of case reports. 8: -
Blood–Brain Barrier Disruption (BBBD)-Based Immunochemotherapy for Primary Central Nervous System Lymphoma (PCNSL), Early Results of a Phase II Study
Kuitunen, Hanne K; Rönkä, Aino LK; Sonkajärvi, Eila M; Isokangas, Juha-Matti; Pyörälä, Marja; Palosaari, Kari AA; Jokimäki, Anna S; Partanen, Anu E; Littow, Harri J; Vakkala, Merja A; Jantunen, Esa J; Huttunen, Mirja E; Marin, Katja J; Aromaa-Häyhä, Annikki MK; Auvinen, Päivi K; Selander, Tuomas; Puhakka, Inka K; Kuittinen, Outi M. 2023. Cancers. 15: -
CD34(+) Cell Mobilization, Autograft Cellular Composition and Outcome in Mantle Cell Lymphoma Patients
Turunen, Antti Samuli; Kuittinen, Outi; Kuitunen, Hanne; Vasala, Kaija; Penttila, Karri; Harmanen, Minna; Keskinen, Leena; Mantymaa, Pentti; Pelkonen, Jukka; Varmavuo, Ville; Jantunen, Esa; Partanen, Anu. 2023. Transfusion medicine and hemotherapy. 50: 428-437 -
Controversies in the Front-Line Treatment of Systemic Peripheral T Cell Lymphomas
Sorigue, Marc; Kuittinen, Outi. 2023. Cancers. 15: -
Estimating the Lifetime Treatment Burden of Patients With Follicular Lymphoma: A Retrospective Study Using Real-World Multicenter Data
Rajamäki, Aino; Hujo, Mika; Sund, Reijo; Prusila, Roosa E.I.; Kuusisto, Milla E.L.; Kuitunen, Hanne; Jantunen, Esa; Mercadal, Santiago; Sorigue, Marc; Sancho, Juan Manuel; Sunela, Kaisa; Kuittinen, Outi. 2023. JCO clinical cancer informatics. 7: -
Follikulaarisen lymfooman muuttuva hoito
Aromaa-Häyhä, Annikki; Auvinen, Päivi; Marin, Katja; Prusila, Roosa; Jokelainen, Otto; Kuittinen, Outi. 2023. Duodecim. 139: 117-125 -
Loss of CD34+ Cells and Effect of the Number of Viable Cryopreserved CD34+ Cells in the Infused Blood Grafts on Hematologic Recovery, Progression-Free Survival and Overall Survival in NHL Patients After Autologous Stem Cell Transplantation
Partanen, Anu; Turunen, Antti; Valtola, Jaakko; Pyörälä, Marja; Kuittinen, Outi; Kuitunen, Hanne; Vasala, Kaija; Penttilä, Karri; Kuittinen, Taru; Mäntymaa, Pentti; Pelkonen, Jukka; Jantunen, Esa; Varmavuo, Ville. 2023. Clinical lymphoma myeloma and leukemia. 23: e428-e435